Literature DB >> 34772841

Clinicopathologic Characteristics and Prognostic Factors of Primary and Recurrent Pleomorphic Adenoma: A Single Institution Retrospective Study of 705 Cases.

Bayan Alzumaili1, Bin Xu2, Maelle Saliba3, Abderhman Abuhashem4, Ian Ganly5, Ronald Ghossein2, Nora Katabi2.   

Abstract

Although pleomorphic adenoma (PA) is benign, it may recur and prompt further treatment with radiotherapy (RT). This study investigated the prognostic features of primary and recurrent PAs. A total of 705 PAs (613 primary and 92 recurrent) were analyzed. The following parameters: age, site and size, status of resection, histologic features, and clinical management were documented and correlated with recurrence-free survival. For primary PAs: The mean patient age was 50 years (female/male: 2/1), the median size was 2.1 cm (range: 0.5 to 9.0 cm), and the most common location was the parotid (92%). Tumors showed the following: complete encapsulation (25%), involvement of the surrounding salivary gland/fat (74%), hypercellularity (26%), ≥10 pseudopods (15%), squamous metaplasia (43%), mitoses (49%), intravascular tumor deposit (n=1), close proximity to nerves (n=2), positive margin (15%), and suboptimal resection (2%). The recurrence rate was 3.4% and malignant transformation was <1%. On univariate analysis, age below 30, mitosis ≥3/10 HPFs, squamous metaplasia, hypercellularity, and suboptimal resection correlated with recurrence-free survival. On multivariate analysis, only age below 30, mitosis ≥3/10 HPF and suboptimal resection predicted recurrence. For recurrent PAs: The resected primary PAs were fragmented in 58%. Forty-eight percent of patients had subsequent recurrences, mostly within 10 years, and 1 patient developed a subsequent malignant transformation. Forty-two percent of patients received RT. On univariate analysis, only RT was associated with better outcome (P=0.033). Young age, high mitoses, and specimen integrity predicted recurrence in primary PA. Recurrent PAs are difficult to eradicate, and 48% of these recurred for the second time, mostly within 10 years.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34772841      PMCID: PMC9106806          DOI: 10.1097/PAS.0000000000001837

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.298


  51 in total

1.  Tumors of the major salivary glands.

Authors:  F W FOOTE; E L FRAZELL
Journal:  Cancer       Date:  1953-11       Impact factor: 6.860

2.  Salivary neoplasms: overview of a 35-year experience with 2,807 patients.

Authors:  R H Spiro
Journal:  Head Neck Surg       Date:  1986 Jan-Feb

3.  Mixed tumors of salivary glands. Long-term follow-up.

Authors:  S O Krolls; R C Boyers
Journal:  Cancer       Date:  1972-07       Impact factor: 6.860

4.  Role of radiotherapy for pleomorphic adenoma.

Authors:  C Wesley Hodge; Christopher G Morris; John W Werning; William M Mendenhall
Journal:  Am J Clin Oncol       Date:  2005-04       Impact factor: 2.339

5.  Atypical features in salivary gland mixed tumors: their relationship to malignant transformation.

Authors:  P L Auclair; G L Ellis
Journal:  Mod Pathol       Date:  1996-06       Impact factor: 7.842

6.  Pleomorphic adenoma - the results of a retrospective analysis of 104 patients treated at the Clinical Department of Cranio-Maxillofacial Surgery, Clinic of Otolaryngology and Laryngologic Oncology of the Military Institute of Medicine.

Authors:  Michał Korba; Aldona Chloupek; Jarosław Dąbrowski; Tomasz Piętka; Wojciech Domański; Barbara Biernacka; Wojciech Leśniak
Journal:  Otolaryngol Pol       Date:  2017-08-31

7.  Prognostic factors for secondary recurrence of pleomorphic adenoma: a 20-year, retrospective study.

Authors:  O Malard; R Wagner; M Joubert; A-S Delemazure; E Rio; N Durand; F Espitalier
Journal:  J Laryngol Otol       Date:  2013-08-20       Impact factor: 1.469

8.  Postoperative radiation therapy for parotid pleomorphic adenoma with close or positive margins: treatment outcomes and toxicities.

Authors:  Shyamal Patel; Waleed F Mourad; Chengtao Wang; Bhaswant Dhanireddy; Catherine Concert; Magdalena Ryniak; Azita S Khorsandi; Rania A Shourbaji; Zujun Li; Bruce Culliney; Rajal Patel; Richard L Bakst; Theresa Tran; Daniel Shasha; Stimson Schantz; Mark S Persky; Kenneth S Hu; Louis B Harrison
Journal:  Anticancer Res       Date:  2014-08       Impact factor: 2.480

Review 9.  Metastasising pleomorphic adenoma: Systematic review.

Authors:  James Knight; Kumaran Ratnasingham
Journal:  Int J Surg       Date:  2015-05-06       Impact factor: 6.071

10.  Pleomorphic adenoma of the parotid: extracapsular dissection compared with superficial parotidectomy--a 10-year retrospective cohort study.

Authors:  Maria Giulia Cristofaro; Eugenia Allegra; Amerigo Giudice; Walter Colangeli; Davide Caruso; Ida Barca; Mario Giudice
Journal:  ScientificWorldJournal       Date:  2014-10-21
View more
  1 in total

Review 1.  Chromosome Translocations, Gene Fusions, and Their Molecular Consequences in Pleomorphic Salivary Gland Adenomas.

Authors:  Göran Stenman; Andre Fehr; Alena Skálová; Vincent Vander Poorten; Henrik Hellquist; Lauge Hjorth Mikkelsen; Nabil F Saba; Orlando Guntinas-Lichius; Carlos Miguel Chiesa-Estomba; Mattias K Andersson; Alfio Ferlito
Journal:  Biomedicines       Date:  2022-08-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.